SCHEDULE: Deep Track Capital Exits Olema Pharma Stake

Deep Track Capital and its affiliates report 0% beneficial ownership in Olema Pharmaceuticals, Inc., indicating a full divestment of their prior stake.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding Olema Pharmaceuticals, Inc.
• The Reporting Persons now beneficially own 0% of the Common Stock of Olema Pharmaceuticals, Inc.
• This filing indicates that the Reporting Persons no longer hold a reportable stake (5% or more) in Olema Pharmaceuticals, Inc.
• The event requiring this filing occurred on December 31, 2025.
• The beneficial ownership calculation is based on 78,652,730 shares of Common Stock outstanding as of November 19, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal for Olema Pharmaceuticals, as the complete divestment by a significant institutional investor like Deep Track Capital could indicate a loss of confidence or a strategic re-evaluation of the investment.

Negatives

• Deep Track Capital and its affiliates have reduced their beneficial ownership in Olema Pharmaceuticals, Inc. to 0%.
• The complete divestment by a significant institutional investor could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that institutional investor movements, particularly significant divestments like this, are closely watched in the biotechnology sector. Such changes can sometimes precede or reflect shifts in market sentiment or specific company prospects, though the filing itself does not provide reasons for the divestment.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for institutional investors whose beneficial ownership falls below the 5% threshold. There are no specific comparable companies or projects mentioned within the filing itself to assess against industry standards.

Stakeholder Impact

• Shareholders: Existing shareholders might react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The complete divestment by Deep Track Capital, a sophisticated institutional investor, signals a lack of confidence in Olema Pharmaceuticals' future prospects. While the filing does not provide reasons, such a move by a major holder often precedes or reflects negative developments, suggesting a 'sell' recommendation for investors to re-evaluate their positions.

Keywords

Olema Pharmaceuticals, Deep Track Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Divestment, Equity Stake